Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Aethlon Medical ( (AEMD) ) has issued an announcement.
On November 5, 2025, Aethlon Medical, Inc. announced it had regained compliance with the Nasdaq’s minimum bid price requirement, following a period of non-compliance due to its stock price falling below $1.00. This development marks a positive shift for the company, as maintaining its Nasdaq listing is crucial for its market presence and investor confidence.
The most recent analyst rating on (AEMD) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Aethlon Medical stock, see the AEMD Stock Forecast page.
Spark’s Take on AEMD Stock
According to Spark, TipRanks’ AI Analyst, AEMD is a Underperform.
Aethlon Medical’s overall stock score is low due to significant financial challenges, including persistent losses and cash flow issues. The technical indicators suggest negative momentum, and the valuation is unattractive given the negative P/E ratio and lack of dividends. While the earnings call presented some positive strategic efforts, such as cost reduction and trial advancements, the hurdles in clinical trials and financial constraints weigh heavily on the stock’s outlook.
To see Spark’s full report on AEMD stock, click here.
More about Aethlon Medical
Aethlon Medical, Inc. operates in the medical technology industry, focusing on developing therapeutic technologies to address unmet needs in health care.
Average Trading Volume: 313,957
Technical Sentiment Signal: Sell
Current Market Cap: $3.44M
Learn more about AEMD stock on TipRanks’ Stock Analysis page.